LONDON (Alliance News) - Motif Bio PLC said it will announce data from two studies of its flagship antibiotic iclaprim at the Infectious Disease Week 2015 conference in San Diego, California.
The conference will run between October 7 and 11. The data will include a study into iclaprim for the treatment of skin and skin structure infections, compared to linezolid, a standard of care treatment in this area. Also to be presented will be a study into iclaprim for hospital-acquired bacterial pneumonia.
Shares in Motif Bio were down 6.4% at 59.50 pence Tuesday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.